Two targets, such as Tubero and Aqab
Daewon Pharmaceutical (CEO Seung-Yeol Baek) announced on the 24th that it has signed a joint promotion contract with Boryeong Pharmaceutical (CEO Ahn Jae-Hyun and Lee Sam-soo) for a new drug for treating hypertension,’Kannab Family (Akab, Tubero)’.
The products sold are’Kannab’, a single drug for hypertension treatment (a drug containing one component), and’Tubero Tablet,’ a combination drug (a drug consisting of two or more ingredients) that is a combination drug for hyperlipidemia. It is’Arkabjeong’.
‘Tubero’ is a product that improves the patient’s medication convenience by combining Kanab’s ingredient’pimasartan’ and hyperlipidemia treatment ingredient’Rosuvastatin’, and was launched in 2016.
‘Arkab’ is a new product launched this year as a combination of’Pimasartan’ and’Atorvastatin’, which is used as a treatment for hyperlipidemia.
With this contract, Daewon Pharmaceutical will be in charge of distribution, sales and marketing of’Tubero’ to all domestic hospitals and clinics. The distribution of’Arkave’ is conducted by Daewon Pharmaceutical, and the sales and marketing are jointly conducted by both companies.
Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical said, “The Kanab Family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model for domestic new drugs.” We look forward to helping more patients improve their quality of life.”
“Based on Daewon Pharmaceutical’s differentiated marketing capabilities and sales know-how, we will contribute to expanding the market share of the’Kannab’ brand,” said Seung-Yeol Baek, Vice Chairman of Daewon Pharmaceutical. “We will expand our product portfolio.”
Copyright © Shin-A Ilbo Unauthorized reproduction and redistribution prohibited